Edition:
India

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.03USD
1:13am IST
Change (% chg)

$-0.16 (-4.87%)
Prev Close
$3.18
Open
$3.15
Day's High
$3.21
Day's Low
$3.03
Volume
417,076
Avg. Vol
426,397
52-wk High
$4.59
52-wk Low
$2.82

Chart for

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule,... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $950.48
Shares Outstanding(Mil.): 270.79
Dividend: --
Yield (%): --

Financials

BRIEF-Amarin estimates net product revenue for Q1 to be about $43 mln

* AMARIN UPDATES FIRST QUARTER REVENUE GUIDANCE, REITERATES FULL YEAR GUIDANCE AND UPDATES ON REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY PROGRESS AND VASCEPA PROMOTION INITIATIVES

04 Apr 2018

BRIEF-Amarin's says 100 pct Mark reached on REDUCE-IT Cardiovascular Outcomes Study for Estimated Onset of Target Primary MACE

* IT CARDIOVASCULAR OUTCOMES STUDY REACHES 100% MARK FOR ESTIMATED ONSET OF TARGET PRIMARY MAJOR ADVERSE CARDIOVASCULAR EVENTS

04 Apr 2018

BRIEF-Amarin Corporation Says ‍Ministry Of Public Health In Lebanon Approved Vascepa

* AMARIN CORPORATION PLC - ‍MINISTRY OF PUBLIC HEALTH IN LEBANON HAS APPROVED VASCEPA​

21 Mar 2018

BRIEF-Amarin Reports Fourth Quarter Loss Of $0.08 Per Share

* AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS

27 Feb 2018

BRIEF-Amarin Prices Public Offering Of American Depositary Shares

* AMARIN PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

30 Jan 2018

BRIEF-Amarin Announces Proposed Public Offering Of American Depositary Shares

* AMARIN ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES

30 Jan 2018

BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China

* AMARIN ANNOUNCES COMMENCEMENT OF VASCEPA CLINICAL DEVELOPMENT IN MAINLAND CHINA Source text for Eikon: Further company coverage:

17 Jan 2018

BRIEF-Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​

* AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK

05 Jan 2018

BRIEF-Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study

* AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018

19 Dec 2017

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations

01 Nov 2017

Competitors

Earnings vs. Estimates